麦默通系统用于微创切除及乳腺病活检68例的临床分析  

CLINICAL ANALYSIS OF MAMMOTOME SYSTEM FOR MINIMALLY INVASIVE EXCISION AND BIOPSY IN TREATMENT OF 68 CASES WITH BREAST DISEASE

作　　者：杨景明[1] 

机构地区：[1]天津市大港医院外二科,天津300270

出　　处：《现代预防医学》2011年第20期4152-4153,共2页Modern Preventive Medicine

摘　　要：[目的]探讨麦默通系统用于微创切除及乳腺病活检68例的临床效果。[方法]分别采用Tru-cut活检针和麦默通系统在超声引导下进行乳腺病活检,并比较两种活检方法的取材成功率和病检符合率。[结果]麦默通组取材成功率为100.00%,病检符合率为100.00%。Tru-cut活检针组中6例因肿块滑动取材不满意或肿块中心坏死及标本呈碎屑状,病理切片不理想,取材成功率为88.00%,与术后病检符合率为86.00%;麦默通组与Tru-cut活检针组相比其取材成功率和病检符合率均明显高于Tru-cut活检针组,且差异有统计学意义(P﹤0.05)。[结论]麦默通活检优于Tru-Cut活检针,是目前患者最满意、创伤最小、最安全、最美观的治疗乳腺肿块的方法,可作为病理活检诊断乳腺疾病首选的取样方法。[ Objective] To investigate the Mammotome system for minimally invasive biopsy resection and 68 cases of breast disease clinical effect. [Methods] This paper used Tru-cut biopsy needle and the Mammotome system for ultrasound- guided biopsy of breast disease, and compared the success rate of biopsy and pathology consistent rate of the two methods. [ Results） The success rate Mammotome group drawn 100.00%, and pathology rate was 100.00%. Tru-cut biopsy needle group, 6 cases of patients were not satisfied because of mass or mass sliding derived central necrosis and the specimens were clastic. Biopsy was not ideal, the success rate was 88.00%, and pathologic study found was 86.00%. The success rate and pathology rate of Mammotome group were significantly higher than that of Tru-cut biopsy needle group, and there was significant difference （P 〈 0.05）. [Conclusion] Mammotome biopsy is superior to Tru-Cut biopsy needle, and it is the most satisfied patients, trauma smallest, safest, most attractive method of treatment of breast lumps, biopsy can be used as the preferred diagnostic sampling of breast disease.

关 键 词：麦默通 微创 切除 乳腺病 活检 

分 类 号：R655.8[医药卫生—外科学]